CYP3A Activity and Expression in Nonalcoholic Fatty Liver Disease

Drug Metabolism and Disposition - United States
doi 10.1124/dmd.115.065979
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Related search

Nonalcoholic Fatty Liver Disease

Hypertension
Internal Medicine
2020English

Nonalcoholic Fatty Liver Disease

Gastroenterology
HepatologyGastroenterology
2002English

Nonalcoholic Fatty Liver Disease in Psoriasis

British Journal of Dermatology
DermatologyMedicine
2018English

Nonalcoholic Fatty Liver Disease in 2020

Gastroenterology
HepatologyGastroenterology
2020English

Ethnicity and Nonalcoholic Fatty Liver Disease

Hepatology
MedicineHepatology
2012English

In Brief: Nonalcoholic Fatty Liver Disease

Pediatrics in Review
MedicineChild HealthPediatricsPerinatology
2010English

Dehydroepiandrosterone in Nonalcoholic Fatty Liver Disease

2012English

The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis

Journal of Clinical and Experimental Hepatology
Hepatology
2015English

Nonalcoholic Fatty Liver Disease and Colorectal Neoplasia

Gastroenterology
HepatologyGastroenterology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy